Cargando…

Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence

Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Susanna B, Cetinkaya-Fisgin, Aysel, Argyriou, Andreas A, Höke, Ahmet, Cavaletti, Guido, Alberti, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579520/
https://www.ncbi.nlm.nih.gov/pubmed/37015772
http://dx.doi.org/10.1136/jnnp-2021-328323
_version_ 1785121741619593216
author Park, Susanna B
Cetinkaya-Fisgin, Aysel
Argyriou, Andreas A
Höke, Ahmet
Cavaletti, Guido
Alberti, Paola
author_facet Park, Susanna B
Cetinkaya-Fisgin, Aysel
Argyriou, Andreas A
Höke, Ahmet
Cavaletti, Guido
Alberti, Paola
author_sort Park, Susanna B
collection PubMed
description Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical work on the onset, progression and outcome of axonal degeneration in CIPN. We review likely triggers of axonal degeneration in CIPN and highlight evidence of molecular pathways involved in axonal degeneration and their relevance to CIPN, including SARM1-mediated axon degeneration pathway. We identify potential clinical markers of axonal dysfunction to provide early identification of toxicity as well as present potential treatment strategies to intervene in axonal degeneration pathways. A greater understanding of axonal degeneration processes in CIPN will provide important information regarding the development and progression of axonal dysfunction more broadly and will hopefully assist in the development of successful interventions for CIPN and other neurodegenerative disorders.
format Online
Article
Text
id pubmed-10579520
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105795202023-10-18 Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence Park, Susanna B Cetinkaya-Fisgin, Aysel Argyriou, Andreas A Höke, Ahmet Cavaletti, Guido Alberti, Paola J Neurol Neurosurg Psychiatry Neuro-Oncology Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence from preclinical and clinical work on the onset, progression and outcome of axonal degeneration in CIPN. We review likely triggers of axonal degeneration in CIPN and highlight evidence of molecular pathways involved in axonal degeneration and their relevance to CIPN, including SARM1-mediated axon degeneration pathway. We identify potential clinical markers of axonal dysfunction to provide early identification of toxicity as well as present potential treatment strategies to intervene in axonal degeneration pathways. A greater understanding of axonal degeneration processes in CIPN will provide important information regarding the development and progression of axonal dysfunction more broadly and will hopefully assist in the development of successful interventions for CIPN and other neurodegenerative disorders. BMJ Publishing Group 2023-11 2023-04-04 /pmc/articles/PMC10579520/ /pubmed/37015772 http://dx.doi.org/10.1136/jnnp-2021-328323 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neuro-Oncology
Park, Susanna B
Cetinkaya-Fisgin, Aysel
Argyriou, Andreas A
Höke, Ahmet
Cavaletti, Guido
Alberti, Paola
Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
title Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
title_full Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
title_fullStr Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
title_full_unstemmed Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
title_short Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
title_sort axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence
topic Neuro-Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579520/
https://www.ncbi.nlm.nih.gov/pubmed/37015772
http://dx.doi.org/10.1136/jnnp-2021-328323
work_keys_str_mv AT parksusannab axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence
AT cetinkayafisginaysel axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence
AT argyriouandreasa axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence
AT hokeahmet axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence
AT cavalettiguido axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence
AT albertipaola axonaldegenerationinchemotherapyinducedperipheralneurotoxicityclinicalandexperimentalevidence